We announce the launch of UNITIOB® (sunitinib) to the medical community.
UNITIOB® (sunitinib) is indicated for the treatment of patients with gastrointestinal stromal tumors (GIST), advanced renal cell carcinoma, adjuvant treatment of patients at high risk of recurrent renal cell carcinoma following nephrectomy, and well-differentiated pancreatic neuroendocrine tumors (PNET) in patients with advanced or unresectable disease.
Varifarma presents UNITIOB® Sunitinib
- Proven efficacy in various conditions
- ADVANCED RENAL CELL CARCINOMA
- ADJUVANT TREATMENT IN PATIENTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA FOLLOWING NEPHRECTOMY GIST FOLLOWING PROGRESSION OR INTOLERANCE TO IMATINIB.
- WELL-DIFFERENTIATED PANCREACTIC NEUROENDOCRINE TUMORS (PNET) IN PATIENTS WITH ADVANCED OR UNRESECTABLE DISEASE.
Click here for more product information